Overview
McDermott Will & Emery advised Maat Pharma, a late-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) aimed at improving the survival of cancer patients through modulation of the immune system, in a EUR13 million capital increase from its historical shareholders, Biocodex, PSIM fund represented by Bpifrance Investissement and an existing American-European investor.
The funds raised will help support the company in advancing its next development milestones, including the submission of the marketing authorization application for MaaT013 in aGvH in Europe, the expansion strategy in the United States, and the conclusion of potential partnerships for its hemato-oncology products in Europe.
The McDermott team involved in this operation was composed of:
Corporate & stock market aspects
- Bertrand Delafaye, Partner
- Sophie Lafay, Counsel
- Lucie Martin, Counsel
- Henri Nalbandyan, Associate
Life Sciences aspects
- Emmanuelle Trombe, Partner
- Amel El Mouttaki, Associate
About McDermott
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
